108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
确定接受他莫昔芬治疗的乳腺癌女性患者子宫内膜厚度的治疗阈值
Authors Huang L, Lu Y, Chen Y, Liu H, An J
Received 2 April 2025
Accepted for publication 10 September 2025
Published 25 September 2025 Volume 2025:17 Pages 3189—3199
DOI https://doi.org/10.2147/IJWH.S531872
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Everett Magann
Lurong Huang,* Ye Lu,* Yanhui Chen,* Hongli Liu, Jian An
Department of Gynecology, Department of Obstetrics and Gynecology, Women and Children’s Hospital, School of Medicine, Xiamen University, Xiamen, 361000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hongli Liu; Jian An, Department of Gynecology, Department of Obstetrics and Gynecology, Women and Children’s Hospital, School of Medicine, Xiamen University, Xiamen, 361000, People’s Republic of China, Email doc79924763@163.com; anjian1994@foxmail.com
Background: Breast cancer is a prevalent malignancy in women that often requires endocrine treatment, such as tamoxifen, which is known to affect endometrial thickness and pose risks of endometrial pathologies.
Objective: This study aimed to determine a clinically relevant threshold for transvaginal ultrasound-measured endometrial thickness in breast cancer patients receiving tamoxifen therapy and assess its predictive value for endometrial pathologies.
Methods: We analyzed a total of 205 endometrial biopsies from women dichotomized into premenopausal and postmenopausal groups. We assessed the clinical and pathological characteristics in relation to the presence of endometrial pathologies, employing receiver operating characteristic (ROC) curves to evaluate the predictive value of endometrial thickness as a diagnostic marker.
Results: Among the study cohort, 11.71% of patients were diagnosed with endometrial hyperplasia, and 3.90% had endometrial cancer. Our findings indicate that women with endometrial pathologies exhibited significantly greater endometrial thickness (P< 0.001) in both premenopausal and postmenopausal cohorts. Notably, demographic and clinical factors including age, body mass index, gravidity, parity, comorbidities, duration of tamoxifen use, and abnormal vaginal bleeding did not differ significantly between groups with or without pathology. The ROC analysis yielded an area under the curve (AUC) of 0.845 for premenopausal and 0.759 for postmenopausal patients, establishing cutoff values of 0.95 cm and 0.55 cm, respectively.
Conclusion: Our research confirms that endometrial thickness serves as a significant clinical indicator for diagnosing endometrial pathologies in breast cancer patients receiving tamoxifen therapy, underscoring the necessity for risk-based strategies to monitor patients with thickened endometria and advocating for timely hysteroscopic intervention when warranted.
Keywords: endometrial pathology, breast cancer, endometrium, cutoff, menopause
Department of Gynecology, Department of Obstetrics and Gynecology, Women and Children’s Hospital, School of Medicine, Xiamen University, Xiamen, 361000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hongli Liu; Jian An, Department of Gynecology, Department of Obstetrics and Gynecology, Women and Children’s Hospital, School of Medicine, Xiamen University, Xiamen, 361000, People’s Republic of China, Email doc79924763@163.com; anjian1994@foxmail.com
Background: Breast cancer is a prevalent malignancy in women that often requires endocrine treatment, such as tamoxifen, which is known to affect endometrial thickness and pose risks of endometrial pathologies.
Objective: This study aimed to determine a clinically relevant threshold for transvaginal ultrasound-measured endometrial thickness in breast cancer patients receiving tamoxifen therapy and assess its predictive value for endometrial pathologies.
Methods: We analyzed a total of 205 endometrial biopsies from women dichotomized into premenopausal and postmenopausal groups. We assessed the clinical and pathological characteristics in relation to the presence of endometrial pathologies, employing receiver operating characteristic (ROC) curves to evaluate the predictive value of endometrial thickness as a diagnostic marker.
Results: Among the study cohort, 11.71% of patients were diagnosed with endometrial hyperplasia, and 3.90% had endometrial cancer. Our findings indicate that women with endometrial pathologies exhibited significantly greater endometrial thickness (P< 0.001) in both premenopausal and postmenopausal cohorts. Notably, demographic and clinical factors including age, body mass index, gravidity, parity, comorbidities, duration of tamoxifen use, and abnormal vaginal bleeding did not differ significantly between groups with or without pathology. The ROC analysis yielded an area under the curve (AUC) of 0.845 for premenopausal and 0.759 for postmenopausal patients, establishing cutoff values of 0.95 cm and 0.55 cm, respectively.
Conclusion: Our research confirms that endometrial thickness serves as a significant clinical indicator for diagnosing endometrial pathologies in breast cancer patients receiving tamoxifen therapy, underscoring the necessity for risk-based strategies to monitor patients with thickened endometria and advocating for timely hysteroscopic intervention when warranted.
Keywords: endometrial pathology, breast cancer, endometrium, cutoff, menopause